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TRAK correlated with LN dose, however, with linear regression R2 was 
less than 0.3 for all LNs which indicates that TRAK cannot be used to 
predict LN dose. 
 
 
Conclusions: BT contributes with considerable dose to pelvic LNs, and 
should be considered in the evaluation of total LN dose,in particular 
when pathological LNs are boosted. In our study the optimised 
BTcontributed with a range of 3.8 - 6.2Gy (D50%) to pelvic LN and 0.5-
1.9 to PAN,CI and ING (D50%). Image guided BT plan optimization had 
minor impact on BT contribution to LN dose.  
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Purpose/Objective: To assess the impact of organ movement and 
deformation on tumour and organ at risk (OAR) dose parameters by 
repeating MR imaging during individual brachytherapy (BT) fractions. 
Materials and Methods: Multiple MR scans during BT were performed 
in 12 patients treated with external beam radiotherapy (EBRT), 
chemotherapy and high dose rate (HDR) image guided adaptive BT. 
The BT schedule consisted of two HDR applications delivering two 
fractions each (2 times 2 fractions of 7Gy). A set of T2-weighted 
transversal, sagittal and coronal MR scans was acquired after insertion 
of the applicator (MRplan). High risk clinical target volume (HR-CTV) 
and the organs at risk (bladder, rectum, and sigmoid) were delineated 
and treatment planning was conducted directly on MR images. Prior to 
irradiation a second MRI set (MRprerad) was obtained. An onset 
applicator based registration with MRplan made evaluation of OAR 
position and volume changes before irradiation possible. Adaptations, 
e.g. deflating gas from the rectum, were applied to several patients 
to keep the rectum at MRprerad similar to the planned situation 
(MRplan). Applicator insertions, MR imaging and HDR dose delivery 
were performed in an adapted BT operation theatre, with afterloader 
secured to the wall. 
For research purposes the treatment plan was evaluated on the 
contours of MRprerad. Calculated dose differences between MRplan 
and MRprerad indicate changes between planned and received dose. 
These differences were evaluated and compared to the data obtained 
in a group of 10 patients that received repeated MR imaging during 
pulsed dose rate (PDR) BT.  
Results: The planned mean total dose (EBRT + BT) for the D90 HR-CTV 
and D2cc of bladder, rectum, and sigmoid were 86±6, 84±9, 64±9, and 
62±6 Gy EQD2, respectively. The mean differences between the 
planned dose and the received dose calculated on MRprerad were 
0.6±1.9, -0.7±3.6, 0.7±4.7, and 1.2±2.9 Gy EQD2, respectively. 
Analyses per HDR fraction (n=48) showed variety in physical mean 
dose differences; -1.0±3.7, -1.5±7.5, 2.6±18.6, and 4.7±21.8 %, 
respectively. The mean differences were small, but large ranges 
occurred especially for rectum and sigmoid of (-59-42) and (-34-76) %, 
respectively (figure1). However, despite these differences OAR 
constraints were exceeded in only 3 patients. Comparison with the 
PDR data showed a reduction of mean and standard-deviation of the 
calculated dose differences of the OAR. In particular for rectum and 
sigmoid, during PDR the mean differences increased systematically 20-
30% compared to only 3-5% in HDR treated patients.  
Conclusions: The introduction of MRprerad results in a more accurate 
estimate of the dose delivered to the patient. Visualization of 
anatomical changes prior to irradiation allows individualized 
interventions and adaptations which can reduce dose uncertainties in 
rectum and sigmoid.  
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Purpose/Objective: Little data exists on the effect of variations of 
bladder volume (BV) on toxicity outcomes for image-guided 
intracavitary brachytherapy (ICB) for cervical cancer. Limited data has 
shown that variable bladder filling at each fraction can vary the 
position of hot spots within the bladder. Recently, it has become our 
center's policy to alternate between small (60cc) and large (300cc) 
bladder filling with the assumption that this might reduce long-term 
bladder toxicity. Objective of this study was to determine if there was 
a correlation between BV variation and long-term bladder toxicity.  
Materials and Methods 
Data for patients treated with ICB from 2008 to 2012 in 3 centers was 
prospectively collected. Patients received 45 Gy in 25 fractions of 
pelvic ± para-aortic EBRT with concurrent chemotherapy followed by 4 
to 5 fractions of ICB. Patient-reported toxicity was measured with 
LENT-SOMA questionnaires at the time of follow-up visits. Dose 
parameters including HR-CTV D90 Bladder D2cc, ICRU bladder dose 
points and BV (based on CT contour) were recorded for each ICB 
fraction. A total dose in EQD2 was generated for each dose 
parameter. Standard deviation for bladder BV between the 4-5 
fractions in each patient was used as a surrogate measure of bladder 
volume variability. Univariate linear regression analyses were 
completed to determine if there was significant correlation between 
dose parameters or BV variabilty and LENT-SOMA bladder scores. 
Results: 79 patients were treated between 2008 and 2012 with ICB for 
cervical cancer with CT-based planning. 45 had stage I, 24 stage II, 9 
stage III and 1 stage IV. ICB dose was 30 Gy in 5 fractions of 6 Gy for 
85% of patients, 26Gy in 4 fractions of 6.5Gy for 7,5% and various 5 
fraction schedules of 26 to 32 Gy for 7.5%. Median follow-up was 22.4 
months. 42 patients had a LENT-SOMA bladder score of 0, 31 had 
grade 1 toxicity, 5 had grade 2 toxicity and 1 had grade 3 toxicity. 
Median total HR-CTV D90 EQD2 was 46.6 Gy10 for ICB alone and 90.6 
Gy10including contribution of EBRT. Median total bladder 2cc EQD2 for 
ICB was 36,9 Gy3. Median interfraction standard deviation (SD) of BV 
was 45.3cc (range: 3.7-178.6). All tests for HR-CTV D90, Bladder D2cc 
and ICRU bladder dose point were not statistically significant for 
correlation with LENT-SOMA bladder scores. Regression analysis for 
bladder volume SD vs.LENT-SOMA scores was statistically significant 
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(r=-0.235, p=0.039), meaning greater BV variability was associated 
with reduced LENT-SOMA bladder scores. 
Conclusions: We believe that we are the first to document an 
association between interfraction variation of bladder volume and 
long-term bladder toxicity outcomes in image-guided ICB for cervical 
cancer.This is consistent with previous data showing that BV variation 
can avoid overlap of high dose regions within the bladder. Such data 
could justify changing current practice in many centers that do not 
routinely use variable bladder filling protocols. Nonetheless, study is 
ongoing to determine the exact effect of BV changes on distribution of 
high dose areas to further validate this recommendation.  
   
OC-0360  
 
N. Nesvacil1, K. Tanderup2, J. Kallehauge2, J. Lindegaard2 3, 
C. Kirisits3 
1
2Aarhus University Hospital, Department of Oncology, Aarhus, 
Denmark  
3
 
 
Purpose/Objective: Recent analysis of dosimetric variations 
occurring, e.g. due to anatomical variations, within and between 
different BT fractions, have revealed that expected intra- and inter-
fraction uncertainties are of the order of 10% for D90 of HR CTV and 
20-30% for D  for organs at risk, for the physical dose of each BT 
fraction (Nesvacil et al. 2012, Radiother Oncol 103, S2, S33). This 
leads to uncertainties in the total treatment dose by up to 4-7 Gy 
dose-response curves. The aim of this simulation study was to 
estimate this impact for target and OAR.  
Materials and Methods: In this numerical experiment, a dose-dose 
response curve was assumed for D90 of HR CTV and D  for OAR, by a 
logit function, corresponding to typical dose-response curves assessed 
from clinical data (e.g. Tanderup et al. (submitted) and Georg et al. 
(2009, Radiother Oncol 91, 173)). 
Dose response uncertainties were simulated by applying typical dose 
variations for HDR cervix BT in the calculations, and compared to the 
initial dose-response curve. 
A custom IDL script was used to simulate realistic total treatment 
dose values for a range of dose levels, taking into account reported 
standard deviations of intra-/inter-fraction variations, i.e., 10% for D90 
HR CTV ( / =10Gy) and 20% for D  of OAR ( / =3Gy), for a 
schedule with 45Gy EBRT and 4 BT fractions.  
For each dose level 10000 patients were simulated by picking 
uncertainties randomly for each BT fraction according to a N(Di, 2) 
distribution, where Di was the physical fractional dose and  the SD 
typical for variations. Simulated fractional doses were transformed 
For each simulated patient, response probabilities were calculated 
based on the assumed 'dose-response' curves for D90 and D . 
Parameters for the initial curves are given in Fig. 1. 
For each expected dose level, the corresponding calculated response 
probability values based on the simulated doses were plotted. Median 
and mean response probabilities of the simulated doses were 
graphically compared with expected response values at each dose 
level.  
 
 
Results: 
Results: In comparison to the expected dose-response curve, the 
simulations indicate a steeper slope in the low dose region and a 
flattening of the curve in the high-dose region. (Fig. 1) The effect is 
more visible in the case of OAR. 
Conclusions: Our preliminary simulations indicate that the predictive 
power of dose-effect relationships may be significantly influenced by 
dosimetric uncertainties. The steepness of the real dose-effect curve 
may be over- or underestimated depending on the investigated dose-
region. Taking into account random uncertainties, and minimizing 
them might lead to a relaxation of commonly used dose constraints 
for OAR, allowing for better coverage of target structures.  
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Purpose/Objective: Traditionally, vaginal dose points have been 
defined at the vaginal source level, thus not providing dose 
information for the entire vagina. Since reliable vaginal 
dosevolume/surface histograms are hardly available, a strategy for 
comprehensive vaginal dose reporting for combined external beam 
radiotherapy (EBRT) and brachytherapy (BT) was established. 
Materials and Methods: An anatomical vaginal reference point was 
defined at the level of the Posterior-Inferior Border of Symphysis 
(PIBS), plus two points at a distance of ±2cm (mid/introitus 
vagina)(Figure 1).For BT points were selected at 12/3/6/9 o'clock for 
the upper vagina, at the applicator ring surface and 5 mm depth 
(Figure 1). A vaginal reference length (VRL) was defined from ring 
centre to PIBS. Fifty-nine patients treated for cervical cancer were 
included into this retrospective feasibility study.  
 
 
Results: The method was applicable for all patients. The mean total 
51.4 Gy (36.6-91.7) and 5.7 Gy (1.7-49.1). At 5 mm depth from the 
ring, doses were respectively 115.4 Gy (53.2-210.7)/103.2 Gy (29.9-
Conclusions: With this novel system, a comprehensive reporting of 
vaginal doses is feasible. The present study has demonstrated large 
dose variations between patients observed in all parts of the vagina. 
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